Telbivudine myopathy in a patient with chronic hepatitis B

International Journal of Clinical Pharmacy

Volumn 34, Issue 3, 2012, Pages 422-425

  Wang, Min ^a,b   Da, Yuwei ^a,b   Cai, Haodong ^c   Lu, Yan ^a,b   Wu, Liyong ^a,b   Jia, Jianping ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adverse effects; Hepatitis B; Myopathy; Telbivudine

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CYANOCOBALAMIN; DIURETIC AGENT; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LACTATE DEHYDROGENASE; LAMIVUDINE; MYOSIN ADENOSINE TRIPHOSPHATASE; TELBIVUDINE; TETRAZOLIUM REDUCTASE; THIAMINE; UBIDECARENONE; VIRUS DNA;

ADULT; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARM WEAKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTRODIAGNOSIS; ELECTROMYOGRAPHY; ELECTRON MICROSCOPE; HEART PALPITATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; HYPERTHERMIA; LABORATORY DIAGNOSIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG EDEMA; LONG TERM CARE; MALE; MICROSCOPY; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE NECROSIS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT; STAINING; TENDON REFLEX; TREATMENT DURATION; VASTUS LATERALIS MUSCLE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; MALE; MUSCULAR DISEASES; THYMIDINE;

EID: 84862997705     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9633-3     Document Type: Article

References (11)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97-107.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-38.
3. Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow. Curr Med Chem. 2006;13(23):2839-55.
4. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009; 136(2):486-95.
5. Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with tel-bivudine. J Viral Hepat. 2011;18(12):892-6.
6. Ojetti V, Gasbarrini A, Migneco A, Flore R, Santoliquido A, De Martini D, et al. Lamivudine-induced muscle mitochondrial toxicity. Dig Liver Dis. 2002;34(5):384-5.
7. Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mito-chondrial DNA. Hepatology. 2009;49(6):2080-6.
8. Amarapurkar DN. Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol. 2007;13(46):6150-5.
9. Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001;12(Suppl 1):119-29.
10. Weaver M, Wolf A, Persohn E, Grenet O, Pognan F. Absence of mitochondrial toxicity of telbuvidine in skeletal muscle cells, hepatocytes, and neuronal cells from rat or human. In: Abstract from the 19th Asian Pacific Association for the Study of the Liver (APASL), February 13-16, 2009, Hong Kong; 2009.
11. Kim BK, Oh J, Kwon SY, Choe WH, Ko SY, Rhee KH, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol. 2009;51(4):829-34.